74 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
, compared to $13.2 million for 2022. The increase was primarily related to higher employee compensation and benefits driven by increased headcount
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition … (excluding for these purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
or other appropriate form, certifying the Non-U.S. Holder’s entitlement to benefits under that treaty. Such form must be provided prior to the payment … may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits
424B5
z78w6
11 Mar 24
Prospectus supplement for primary offering
4:06pm
424B4
rt19v a54iujso93r8k
8 Jan 24
Prospectus supplement with pricing info
4:11pm
8-K
EX-99.1
3u6bqsoiarh
4 Jan 24
Other Events
4:21pm
8-K
EX-99.1
q2ql1l8f irtkpfly
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
clqt5uuaaj8yuts19wr
12 Sep 23
Other Events
7:00am
8-K
EX-99.1
6at9wd16qsaqdl 4np4s
24 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
yl8w0
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.2
lbp 3tbnc
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
0fvbrnm
1 May 23
Departure of Directors or Certain Officers
7:30am
8-K
EX-10.1
0keugknl67v169g l3x
1 May 23
Departure of Directors or Certain Officers
7:30am